Broadview Ventures Inc’s Post

Nice background of Dr. Slamon life and on the principals in the discovery and development of trastuzumab

Discover the inspiring journey of Mick, a participant in a new groundbreaking mesothelioma trial. Learn how a new drug is revolutionizing treatment and offering hope to patients worldwide, and read Mick's remarkable story of survival and the promising future of mesothelioma research. https://lnkd.in/g5BXbgyY #mesotheliomatreatment #mesothelioma #hopeandhealing

After decades of research, there remains a dearth of impactful treatments for complex, neurological diseases like Alzheimer’s, Parkinson’s and Rett syndrome. Lucy Therapeutics, who today announced $12.5 million in additional funding co-led by Engine Ventures and Safar Partners, with new participation from Bill Gates, Parkinson's UK, and The Michael J. Fox Foundation for Parkinson's Research, believes we must move away from the siloed, genetic-only approach to studying neurological disease to truly break through. LucyTx seeks to understand the mitochondrial roots of complex diseases, ultimately identifying new drug targets by analyzing a wide range of disease drivers including environmental and genetic factors. With three drug discovery programs already in its pipeline, we look forward to seeing what’s next for the company. https://lnkd.in/eq8m_DFA

Coya Therapeutics is based on the lifesaving work of Dr. Stanley Appel that has shown Tregs can be the key to treating these #neurodegenerative diseases. Learn more about the science from Stanley himself here: https://lnkd.in/eXfqqjKV #CoyaTherapeutics #Research #Tregs #DrugDiscovery

"The 12-month results from the PARADIGM Phase IIb study are encouraging, showing slowing disease progression and improved survival outcomes. This new analysis highlights PrimeC's ability to regulate the iron panel in people living with ALS, underscoring the drug's target engagement. These findings strongly support the proceeding to phase 3 testing of PrimeC in ALS." #NeuroSenseTherapeutics #ALSTreatment #ClinicalTrial #BiomarkerData #HealthcareInnovation #ProudMoment NeuroSense Therapeutics https://lnkd.in/dzVT6QWJ

From the article: “The grant is part of MJFF’s Parkinson’s Disease Therapeutics Pipeline Program, which aims to foster therapeutic developments that meet the unmet medical needs of those with PD. The program’s goal is to fund research that could prevent, halt, or delay disease progression, or alleviate daily symptoms.” Follow me for tips and inspiration on living with Young Onset Parkinson’s disease. I am John Andrejack.This is a message of Hope! #parkinsonslookslikeme #parkinsonsdisease #hope #hopetheory #parkinsonsresources #stemcells #stemcellresearch #stemcell #stemcelltransplant #stemcellstransplant #parkinsonscommunity#parkinsonsdiseasefoundation #michaeljfox #togetherforsharon #parkinsonsdiseaseawareness #FUYOPD#yopdnetwork #michaeljfoxfoundation @parkinsondotorg @michaeljrfoxorg @yopdnetwork

Gene&Cell Therapy >> 2seventy bio, Bristol Myers end late-stage Abecma study in multiple myeloma: 2seventy bio and its partner Bristol Myers Squibb said Wednesday that they are discontinuing enrollment in the Phase 3 KarMMa-9 study investigating Abecma in patients with newly diagnosed multiple myeloma. 2seventy CEO Chip Baird wrote in a statement that the decision was made after a “rigorous review of the business case for the KarMMa-9 study” and that there’s been a “greatly improved” treatment landscape in the newly diagnosed setting. Chip Baird In a separate release, Bristol Myers added there were enrollment difficulties as there were fewer eligible patients for the study due to “the evolution of more intense and prolonged induction therapies.” The trial has been open for over a year in 18 countries but only 10% of the study population has been accrued so far, the company added. The trial had a target of 618 patients, according to ClinicalTrials.gov. For its part, the trial discontinuation would help 2seventy break even next year. “Consistent with our focus on capital allocation and creating value for all stakeholders, we anticipate this decision will conserve over $80 million in near-term expenditures and accelerate our path to breakeven in 2025,” Baird added. 2seventy and Bristol Myers were evaluating the CAR-T therapy in the trial alongside lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma who had a suboptimal response to an autologous stem cell transplant. The companies scored an expanded approval from the FDA for Abecma in April in the third-line setting, following its initial approval in fifth-line patients, despite concerns over a higher rate of death in early treatment among patients who took the drug compared to those who received standard regimens. “Abecma continues to show encouraging signs of growth with an expanded label in the third line and a differentiated safety profile,” Baird added. In its Tuesday announcement, 2seventy wrote that it expects 2024 third-quarter Abecma revenue growth in the US of around 30% from second-quarter revenue of $54 million. #lucidquest #genetherapy #celltherapy

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> 2seventy bio, Bristol Myers end late-stage Abecma study in multiple myeloma: 2seventy bio and its partner Bristol Myers Squibb said Wednesday that they are discontinuing enrollment in the Phase 3 KarMMa-9 study investigating Abecma in patients with newly diagnosed multiple myeloma. 2seventy CEO Chip Baird wrote in a statement that the decision was made after a “rigorous review of the business case for the KarMMa-9 study” and that there’s been a “greatly improved” treatment landscape in the newly diagnosed setting. Chip Baird In a separate release, Bristol Myers added there were enrollment difficulties as there were fewer eligible patients for the study due to “the evolution of more intense and prolonged induction therapies.” The trial has been open for over a year in 18 countries but only 10% of the study population has been accrued so far, the company added. The trial had a target of 618 patients, according to ClinicalTrials.gov. For its part, the trial discontinuation would help 2seventy break even next year. “Consistent with our focus on capital allocation and creating value for all stakeholders, we anticipate this decision will conserve over $80 million in near-term expenditures and accelerate our path to breakeven in 2025,” Baird added. 2seventy and Bristol Myers were evaluating the CAR-T therapy in the trial alongside lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma who had a suboptimal response to an autologous stem cell transplant. The companies scored an expanded approval from the FDA for Abecma in April in the third-line setting, following its initial approval in fifth-line patients, despite concerns over a higher rate of death in early treatment among patients who took the drug compared to those who received standard regimens. “Abecma continues to show encouraging signs of growth with an expanded label in the third line and a differentiated safety profile,” Baird added. In its Tuesday announcement, 2seventy wrote that it expects 2024 third-quarter Abecma revenue growth in the US of around 30% from second-quarter revenue of $54 million. #lucidquest #genetherapy #celltherapy

🌟 𝗠𝗲𝗲𝘁 𝘂𝘀 𝗮𝘁 𝗧𝗵𝗲 𝗟𝗶𝘃𝗲𝗿 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟰 – 𝗔𝗔𝗦𝗟𝗗 𝗶𝗻 𝗦𝗮𝗻 𝗗𝗶𝗲𝗴𝗼! 🌟 🚀 We are excited to announce our participation in 𝗧𝗵𝗲 𝗟𝗶𝘃𝗲𝗿 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟰, hosted by the American Association for the Study of Liver Diseases (AASLD), from 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟱-𝟭𝟵, 𝟮𝟬𝟮𝟰, in 𝗦𝗮𝗻 𝗗𝗶𝗲𝗴𝗼, 𝗖𝗮𝗹𝗶𝗳𝗼𝗿𝗻𝗶𝗮! 🧬 Ha-Yeon KIM-PENARD, PhD, and Dan Georgess, PhD, Chief Scientific Officer, will be there to discuss how our 𝗵𝘂𝗺𝗮𝗻𝗶𝘇𝗲𝗱 𝗹𝗶𝘃𝗲𝗿 𝗺𝗼𝘂𝘀𝗲 𝗺𝗼𝗱𝗲𝗹 (hu-liver) is driving advancements in preclinical research for liver diseases such as hepatitis, MASH, fibrosis, and more. These models are crucial for supporting drug development and therapeutic innovations. If you're attending, don’t miss the chance to meet Ha-Yeon and Dan and learn how we can accelerate your liver research projects with our innovative solutions! 📅 𝗦𝗰𝗵𝗲𝗱𝘂𝗹𝗲 𝗮 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 𝗵𝗲𝗿𝗲: https://lnkd.in/ewmrGy3m 🤝 𝗦𝗲𝗲 𝘆𝗼𝘂 𝗮𝘁 𝗧𝗵𝗲 𝗟𝗶𝘃𝗲𝗿 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗶𝗻 𝗦𝗮𝗻 𝗗𝗶𝗲𝗴𝗼! 🔗 More info: https://lnkd.in/eVXAzFwz #TLM24 #HumanizedMouseModels #LiverResearch #PreclinicalResearch

Bredec Group BredecInnovation Digital Therapeutics: The Future of Chronic Disease Management is Here! - MarketScale: The intersection of technology and healthcare has ushered in an era of unprecedented innovation, transforming the way chronic and complex ... inquiry@bredec.com Inquiry@bredec.com